Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on June 4, 2025
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
GlobeNewswire
·
June 4, 2025
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer …
Salsify Launches FeedbackIQ to Streamline GDSN with AI
GlobeNewswire
·
June 4, 2025
BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Salsify, the Product Experience Management (PXM) platform empowering brand manufacturers, distributors, and retailers to win on the digital shelf, today announced a significant enhancement to its Global Data …
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
GlobeNewswire
·
June 4, 2025
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data2 for targeting HER-2 …
Melissa’s Azure Integration of SSIS Components Extends Data Quality to the Cloud
GlobeNewswire
·
June 4, 2025
RANCHO SANTA MARGARITA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- As more enterprises migrate to the cloud in pursuit of scalability, speed, and simplified infrastructure, data quality often remains a bottleneck or development challenge. In response, …
Elicio Therapeutics Secures $10 Million in Financing
GlobeNewswire
·
June 4, 2025
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage …
Repeat: Rocket Doctor, a Treatment.com AI company, Joins Larta Institute’s 2025 Heal.LA Accelerator Cohort to Expand Access to Virtual Care
GlobeNewswire
·
June 4, 2025
One of 15 companies selected across critical areas including chronic disease, women’s health, and mental health. Program provides mentorship, regulatory guidance, and funding access to help scale solutions that improve care access and equity. Rocket Doctor …
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
GlobeNewswire
·
June 4, 2025
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society …
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewswire
·
June 4, 2025
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04 …
AgEagle Aerial Systems Secures International Sale of eBee VISION Drones to Paraguayan Government
GlobeNewswire
·
June 4, 2025
Strategic Latin American Deal Expands AgEagle’s Global UAS Presence WICHITA, Kan., June 04, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, announces the sale of two eBee …
Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector
GlobeNewswire
·
June 4, 2025
Greensboro, NC, June 04, 2025 (GLOBE NEWSWIRE) -- Global Technologies, LTD (OTCPK: GTLL), a public, multi-operational company focused on innovation in health and wellness, recently announced corporate developments and commercial milestones signaling a bold …
reAlpha Appoints Mike Logozzo as CEO to Accelerate Growth
GlobeNewswire
·
June 4, 2025
DUBLIN, Ohio, June 04, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (“reAlpha” or the “Company”), an AI-powered real estate technology company, today announced a strategic leadership transition to support its next phase of growth. Effective …
NobleAI Introduces Powerful, Practical AI Solutions For Chemistry and Energy
GlobeNewswire
·
June 4, 2025
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- NobleAI announced today commercial availability of its best-in-class VIP (Visualizations, Insights …
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 4, 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The …
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
GlobeNewswire
·
June 4, 2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of- …
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
GlobeNewswire
·
June 4, 2025
REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, …
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire
·
June 4, 2025
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as …
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
GlobeNewswire
·
June 4, 2025
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on …
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 4, 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, …
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
GlobeNewswire
·
June 4, 2025
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND …
Revive Therapeutics Advances with Next-Generation Bucillamine Development
GlobeNewswire
·
June 4, 2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is …